Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

GlycoMimetics to Present at Four Investor Conferences This Month

GlycoMimetics,Inc.
Posted on: 07 Mar 18

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will present at four investor conferences during the month of March, including:

30 th Annual ROTH Conference
March 11 – 14, 2018, The Ritz Carlton, Dana Point, CA
CFO Brian Hahn will present on March 12 at 3:30 p.m. PT.

Cowen 38 th Annual Health Care Conference
March 11 – 14, 2018, Copley Place Marriott, Boston, MA
CEO Rachel King will present on March 14 at 9:20 a.m. ET.

BioCentury: 25 th Annual Future Leaders in the BioTech Industry
March 23, 2018, Millennium Broadway Hotel & Conference Center, New York, NY
Mrs. King will present in room 311 at 2:30 p.m. ET.

Needham & Company’s 17 th Annual HealthCare Conference
March 27 – 28, 2018, Westin Grand Central Hotel, New York, NY
Mrs. King will present on March 27 at 8:00 a.m. ET.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is currently being evaluated in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180307005331/en/

Business Wire
www.businesswire.com

Last updated on: 07/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.